AI assistant
IMMUTEP LIMITED — Board/Management Information 2010
Jul 26, 2010
65122_rns_2010-07-26_cdf1009e-35b5-48c9-945b-388bdfb86bc8.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [193 x 52] intentionally omitted <==
ASX/Media Release
27 July 2010
RESIGNATION OF DIRECTOR
Prima BioMed Ltd (ASX: PRR) advises that Ata Gokyildirim, a Director of the Company has resigned effective today 27 July 2010.
ENDS
For further information please contact:
Mr Martin Rogers Managing Director Prima BioMed Ltd Ph: +61 428 268 357 E:[email protected]
Website: www.primabiomed.com.au
About CVac™ Ovarian Cancer Treatment
CVac™ is Prima BioMed’s lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.
There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b by 2010.
Regulatory approval and commercialisation of CVac™ is the core focus for Prima.
About Prima BioMed
Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima’s lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is in the final stages of US FDA approval and eventual commercialisation.
The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.
Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889